T

Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM

Watchlist Manager
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Watchlist
Price: 3 399.45 INR -0.61%
Market Cap: 1.2T INR
Have any thoughts about
Torrent Pharmaceuticals Ltd?
Write Note

Torrent Pharmaceuticals Ltd
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Torrent Pharmaceuticals Ltd
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Gross Profit
â‚ą84.8B
CAGR 3-Years
12%
CAGR 5-Years
8%
CAGR 10-Years
10%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Gross Profit
â‚ą212.7B
CAGR 3-Years
16%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Gross Profit
â‚ą177.7B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
10%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Gross Profit
â‚ą398.2B
CAGR 3-Years
14%
CAGR 5-Years
12%
CAGR 10-Years
8%
Lupin Ltd
NSE:LUPIN
Gross Profit
â‚ą147B
CAGR 3-Years
13%
CAGR 5-Years
7%
CAGR 10-Years
6%
M
Mankind Pharma Ltd
NSE:MANKIND
Gross Profit
â‚ą69.4B
CAGR 3-Years
17%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Torrent Pharmaceuticals Ltd
Glance View

Market Cap
1.2T INR
Industry
Pharmaceuticals
Economic Moat
Narrow

In the bustling realm of Indian pharmaceuticals, Torrent Pharmaceuticals Ltd. has carved out a notable niche, emerging from the industrious land of Gujarat. Founded in 1959, this company has transformed from a modest player to a major force in the industry, traversing the complexities of pharmaceutical manufacturing and global distribution. At its core, Torrent Pharmaceuticals is driven by a commitment to healthcare innovation and therapeutic excellence. The company systematically engages in developing, manufacturing, and marketing a wide array of generic pharmaceutical products primarily targeting cardiovascular, central nervous system, gastro-intestinal, anti-infective, and anti-diabetic therapeutic categories. This diverse product portfolio positions Torrent not just as a provider of remedies but as a critical player in improving health outcomes across numerous demographics and geographies. Torrent Pharmaceuticals operates on a robust business model that effectively integrates research, development, and widespread distribution to generate revenue. The company channels significant resources into its R&D capabilities, perpetually expanding its pipeline to introduce more effective and affordable medications. This ongoing innovation supports their competitive edge while fortifying their catalog of offerings. Additionally, Torrent's strategic alliances and acquisitions—most notably, the key acquisition of Elder Pharmaceuticals' branded domestic formulations business in India—have further catapulted its market presence both domestically and internationally. By leveraging its extensive marketing network and manufacturing capabilities compliant with international standards, Torrent not only bankrolls its growth through product sales but also ensures global reach, cementing its role as a pivotal component of the healthcare landscape.

TORNTPHARM Intrinsic Value
1 989.4 INR
Overvaluation 41%
Intrinsic Value
Price
T

See Also

What is Torrent Pharmaceuticals Ltd's Gross Profit?
Gross Profit
84.8B INR

Based on the financial report for Sep 30, 2024, Torrent Pharmaceuticals Ltd's Gross Profit amounts to 84.8B INR.

What is Torrent Pharmaceuticals Ltd's Gross Profit growth rate?
Gross Profit CAGR 10Y
10%

Over the last year, the Gross Profit growth was 13%. The average annual Gross Profit growth rates for Torrent Pharmaceuticals Ltd have been 12% over the past three years , 8% over the past five years , and 10% over the past ten years .

Back to Top